Ultragenyx Pharmaceutical (NASDAQ:RARE) is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases. The company is known for its innovative approach to gene therapy, aiming to address unmet medical needs. Ultragenyx competes with other biotech firms in the rare disease space, striving to bring effective therapies to market.
On March 12, 2026, Bank of America Securities reiterated its “Buy” rating for Ultragenyx, suggesting that the stock’s current valuation does not fully reflect the potential of its pipeline. At that time, the stock was priced at $21.43. This endorsement highlights the confidence in Ultragenyx’s future prospects, particularly in its gene therapy developments.
Ultragenyx recently announced promising results from a late-stage trial of its experimental gene therapy. This therapy has shown effectiveness in managing ammonia levels in patients with a rare inherited disorder. This advancement underscores Ultragenyx’s dedication to pioneering gene therapy solutions, which could significantly impact the treatment landscape for this condition.
Despite the positive trial results, the stock price of RARE is currently $21.44, reflecting a decrease of 3.46% or $0.77. Today, the stock has fluctuated between a low of $21.12 and a high of $22.29. Over the past year, RARE has experienced a high of $42.37 and a low of $18.41, indicating significant volatility.
Ultragenyx’s market capitalization is approximately $2.07 billion, with a trading volume of around 544,561 shares on the NASDAQ exchange. These figures suggest a moderate level of investor interest and activity, as the company continues to advance its pipeline and explore new therapeutic opportunities.
